Azenta 2025 Q4 Earnings Strong Turnaround as Net Income Surges 810%

Azenta (AZTA), ranked by market capitalization, reported fiscal 2025 Q4 earnings on Nov 21st, 2025. The company exceeded revenue expectations and delivered a remarkable net income turnaround, signaling operational and strategic progress. Azenta also provided optimistic 2026 guidance, emphasizing margin expansion and disciplined capital deployment.

Azenta’s total revenue rose to $159.19 million in Q4 2025, a 5.7% increase from $150.60 million in the prior year. The Products segment contributed $48.02 million, while Services accounted for $111.17 million, highlighting the company’s diversified revenue streams.

Azenta returned to profitability with EPS of $1.03 in Q4 2025, reversing a $0.14 loss per share in 2024 Q4. Net income surged 810% to $47.14 million from a $6.64 million loss, reflecting robust operational improvements. The company’s impressive 810% net income turnaround and EPS rebound underscore its successful operational and strategic initiatives.

Post-earnings, Azenta’s stock surged 17.28% weekly and 10.03% month-to-date, reflecting strong investor confidence. While the stock edged up 2.62% in the latest trading day, its performance aligns with the company’s improved financial outlook and strategic clarity.

CEO John P. Marotta emphasized Azenta’s resilience amid macroeconomic headwinds, crediting the Azenta Business System (ABS) for fostering accountability and productivity. The company’s strategic priorities include core growth, margin expansion, and disciplined capital deployment, with a focus on automation and digital workflows. Marotta highlighted a leaner structure, $546 million in cash, and a strong balance sheet as key enablers of outperforming market expectations.

Azenta guided to 3–5% organic revenue growth in fiscal 2026, with 300 bps adjusted EBITDA margin expansion and >30% free cash flow improvement. Sample Management Solutions and Multiomics segments are expected to drive growth, while first-quarter revenue may decline 1–2% year-over-year due to seasonal factors.

Additional News

Azenta’s recent strategic updates include a potential B Medical Systems divestiture under consideration, which could unlock value for shareholders. The company also announced an upcoming Investor Day on December 10, 2025, where it will detail its 2026 growth strategy and operational roadmap. Analyst firm Needham raised its price target to $42 from $40, citing improved financial metrics and a robust cash position.

**

**

Azenta’s strong Q4 performance and strategic clarity have positioned it to capitalize on macro tailwinds, including customer consolidation and outsourcing trends. With a focus on operational excellence and disciplined capital allocation, the company aims to deliver sustainable growth and shareholder value in 2026.